The incidence of pancreatic cancer increased in China, while the overall survival is not satisfactory. We still facing lots of problems, national wide standardized treatment for pancreatic cancer is improving, but far from satisfied, lacking of center of excellence in pancreatic cancer treatment in some province, different insurance coverage for cancer therapy in different region result in different level of medical service, especially the rate of adjuvant therapy, On the other hand, the current status of PDAC in improving, such as growing acceptance of evidence-based pancreatic cancer treatment, such as new adjuvant therapy, more patients accepted surgery; more and more high level clinical trials are conducting, and more new drugs developed in China.